The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHGE | -54.96% | -99.58% | -66.53% | -100% |
| S&P | +13.14% | +87.24% | +13.37% | +142% |
BiomX, Inc. operates as a clinical-stage microbiome company. It engages in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis, and colorectal cancer. The firm discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$1.24M | -285.4% |
| Market Cap | $14.07M | -24.1% |
| Market Cap / Employee | $0.25M | 0.0% |
| Employees | 57 | -19.7% |
| Net Income | -$9.17M | -280.9% |
| EBITDA | -$7.30M | 28.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.91M | -67.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.29M | -38.9% |
| Short Term Debt | $1.30M | 18.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -86.77% | -50.7% |
| Return On Invested Capital | -91.99% | -6.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.19M | 11.4% |
| Operating Free Cash Flow | -$7.18M | 11.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.41 | 2.37 | 23.11 | -1.73 | -279.68% |
| Price to Tangible Book Value | 63.61 | -29.31 | -34.45 | -22.87 | 251.29% |
| Enterprise Value to EBITDA | -2.79 | -2.62 | -3.79 | -4.63 | 131.23% |
| Return on Equity | -189.6% | -68.2% | -99.4% | -154.5% | 111.80% |
| Total Debt | $9.58M | $9.29M | $9.38M | $6.58M | -32.46% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
